Life sciences are an integral component of modern existence, woven into the fabric of humanity. Technological advancements have propelled the impact of life sciences in the modern world, delivering impact for millions of people across the globe.
Many new life science startups have already made a profound impact in the business world. Others are in the early stages of research and development, positioned to reach influential status via positive societal impact.
To help you stay on top of the latest trends, we have created a list of top startup companies worth following in 2020. This list includes businesses launched no earlier than 2017, with the five top startups ranked for collaborations, finance, pipeline and innovation.
Here are some of the most up-and-coming life science companies which have already made a profound industry impact. These appear set to transcend the business landscape as we know it.
One of the more recent startups on the list, Anthos, is at the forefront of digital innovation. The company was launched by Blackstone Life Sciences and Anthos Therapeutics in 2019, which donated $250 million to get the company off the ground.
Athos is focused on developing next-generation treatments for patients with high-risk cardiovascular patients. This work is highly relevant to healthcare, as cardiovascular disease is a pressing issue for millions of people across the globe. The company’s leading asset it’s developing is MAA868, an antibody which is still in development.
Launched in 2018, Cerevel Therapeutics specializes in developing drugs for Central Nervous System (CNS) disorders. The company was founded by Bain Capital and Pfizer, which collectively donated a staggering $350 million to support company operations.
Pfizer has also offered Cerevel some neuroscience assets. These include three clinical-stage compounds and several pre-clinical compounds that target CNS disorders, such as Alzheimer’s disease, epilepsy, and Parkinson’s disease.
Moreover, Cerevel has already conducted clinical trials on two new compounds, which are intended to address Parkinson’s disease, epilepsy and psychosis.
Cyclerion Therapeutics is a spin-off of Ironwood Pharmaceuticals, a hugely influential organization with a small fortune at their disposal. This startup has branched off with a staggering $175 million in private placements, enabling the company to go from strength to strength and expand its business operations.
Cyclerion leverages sGC pharmacology, which has tremendous potential to target serious illnesses and orphan diseases. There are five separate sGC stimulator programs, each of which is designed for unique target tissues. Olinciguat is one of the more recent drugs to be developed by the company, currently in Phase II of clinical trials for sickle cell disease.
In addition, the drug praliciguat is also being tested for its potential treatment of diabetic nephropathy. Cyclerion is also currently developing IW-6463, which is entering Phase I for tackling serious CNS health concerns.
Created by Versant Ventures, Century Therapeutics was launched in 2019. This startup has recently received $250 million in investments from Fujifilm Cellular Dynamics, Bayer and Versant. Century Therapeutics develops innate immune effector cell therapies and iPSC-derived adaptive cell therapies for next-generation immune-oncology treatments.
One of California’s most promising life science startups, Mirum Pharmaceuticals was launched in 2018, supported by an impressive $120 million in financial backing. The business is focused on licensing maralixibat, a drug designed to treat Alagille syndrome (ALGS) and genetic liver diseases affecting children.
Phase II trials demonstrated positive results, prompting a July 2019 initial public offering (IPO), which raised $75 million.
These are just a few of the highly promising life science startups poised for success in 2020 and beyond. Importantly, the companies listed hold tremendous promise for the betterment of humanity.